Premium
Comparative Study of Combination Chemotherapy of Ovarian Cancer: Cyclophosphamide, Adriamycin and Cisplatin versus 5‐Fluorouracil, Cyclophosphamide and Mitomycin C
Author(s) -
Sawada Masumi,
Yamasaki Masato,
Urabe Takeshi,
Ozaki Masami,
Yanagita Takao,
Takayama Katsumi,
Taki Ichiro
Publication year - 1990
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1990.tb00355.x
Subject(s) - cyclophosphamide , cisplatin , fluorouracil , mitomycin c , medicine , oncology , chemotherapy , ovarian cancer , doxorubicin , combination chemotherapy , pharmacology , cancer research , cancer , surgery
CAP, a multiple‐drug combination therapy using cyclophosphamide (750 mg/m 2 ), adriamycin (20–30 mg/m 2 ) and cisplatin (50–75 mg/m 2 ), was applied to 69 cases of epithelial ovarian cancer. The results of this therapy were compared with those of FAM (involving 5‐fluorouracil, cyclophosphamide and mitomycin C) in 47 cases of the same cancer, retrospectively. The 5‐year survival rate was 61.6% for cases treated with CAP and 56.3% for cases treated with FAM. All 9 patients at stage Ia treated with CAP are free of disease, however, 3 patients out of 13 at stage la treated with FAM experienced a recurrence of the disease and died. In stage III and IV cases with detectable lesions, a response was observed in 61.3% (19/31) treated with CAP and in 10.5% (2/19) treated with FAM.